Metabolic characteristics of programmed cell death‐ligand 1‐expressing lung cancer on 18F‐fluorodeoxyglucose positron emission tomography/computed tomography

Programmed cell death‐1 (PD‐1) and programmed cell death‐ligand 1 (PD‐L1) have been identified as novel targets of immunotherapy of lung cancer. In present study, we evaluated the metabolic characteristics of lung cancer by using 18F‐fluorodeoxyglucose positron emission tomography/computed tomography (18F‐FDG PET/CT) with regard to PD‐L1 protein expression. PD‐L1 protein expression was evaluated by immunohistochemistry with the antibody clone SP142 in 579 surgically resected primary lung cancer patients. Cases with less than 5% tumor membrane staining were considered negative. We examined the association between the frequency of PD‐L1 protein expression and the maximum standardized uptake value (SUVmax) in preoperative 18F‐FDG PET/CT. The cut‐off values for SUVmax were determined by receiver operating characteristic curve analyses. The SUVmax was significantly higher in nonsmall cell lung cancer (NSCLC) patients with PD‐L1 protein expression compared with those without PD‐L1 protein expression (P < 0.0001). However, there was no correlation between SUVmax and PD‐L1 protein expression in patients with neuroendocrine tumors (P = 0.6545). Multivariate analysis revealed that smoking, the presence of pleural invasion, and high SUVmax were independent predictors of PD‐L1 positivity. PD‐L1‐expressing NSCLC had a high glucose metabolism. The SUVmax in preoperative 18F‐FDG PET/CT was a predictor of PD‐L1 protein expression in patients with NSCLC.

• Publication year

  2017

• Venue

  Cancer Medicine

• Publication date

  2017-10-04

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/cam4.1215PMID 28980429PMCID 5673920
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The expression of PD-L1 protein as a prognostic factor in lung squamous cell carcinoma.

  2017cited by this paper
• Metabolic characteristics of programmed cell death‐ligand 1‐expressing lung cancer on 18F‐fluorodeoxyglucose positron emission tomography/computed tomography

  2017cited by this paper
• Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1).

  2016influential reference
• An Immunohistochemical Analysis of PD-L1 Protein Expression in Surgically Resected Small Cell Lung Cancer Using Different Antibodies and Criteria.

  2016cited by this paper
• Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer.

  2016cited by this paper
• Clinical Significance of PD‐L1 Protein Expression in Surgically Resected Primary Lung Adenocarcinoma

  2016cited by this paper
• Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer

  2016cited by this paper
• Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer.

  2016cited by this paper
• Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery

  2016cited by this paper
• Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

  2015cited by this paper
• Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers.

  2015cited by this paper
• The Warburg effect in mycobacterial granulomas is dependent on the recruitment and activation of macrophages by interferon‐γ

  2015cited by this paper
• Immune Checkpoint Blockade in Cancer Therapy.

  2015cited by this paper
• Molecularly targeted therapies in non-small-cell lung cancer annual update 2014.

  2015cited by this paper
• PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy

  2015cited by this paper
• Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.

  2015cited by this paper
• Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

  2014cited by this paper
• Impact of initial PET/CT staging in terms of clinical stage, management plan, and prognosis in 592 patients with non-small-cell lung cancer

  2014cited by this paper
• Prognostic and Therapeutic Implications of Aromatase Expression in Lung Adenocarcinomas with EGFR Mutations

  2014cited by this paper
• Biological significance of 18F-FDG uptake on PET in patients with non-small-cell lung cancer.

  2014cited by this paper
• Programmed Cell Death 1 (PD-1) and Its Ligand (PD-L1) in Common Cancers and Their Correlation with Molecular Cancer Type

  2014cited by this paper
• New targetable oncogenes in non-small-cell lung cancer.

  2013cited by this paper
• Metabolic and metastatic characteristics of ALK-rearranged lung adenocarcinoma on FDG PET/CT.

  2013cited by this paper
• The Warburg effect then and now: From cancer to inflammatory diseases

  2013cited by this paper
• The blockade of immune checkpoints in cancer immunotherapy

  2012cited by this paper
• Cancer statistics, 2012

  2012cited by this paper
• Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

  2012cited by this paper
• Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.

  2012cited by this paper
• Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer

  2011cited by this paper
• 18F-FDG uptake and EGFR mutations in patients with non-small cell lung cancer: a single-institution retrospective analysis.

  2010cited by this paper
• Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation

  2009cited by this paper
• 18F-FDG Uptake in Lung, Breast, and Colon Cancers: Molecular Biology Correlates and Disease Characterization*

  2009cited by this paper
• Comparison of aspects of smoking among the four histological types of lung cancer

  2008cited by this paper
• Relationship Between Non-small Cell Lung Cancer FDG Uptake at PET, Tumor Histology, and Ki-67 Proliferation Index

  2008cited by this paper
• FDG uptake, glucose transporter type 1, and Ki-67 expressions in non-small-cell lung cancer: correlations and prognostic values.

  2007cited by this paper
• Molecularly-targeted therapies for non-small cell lung cancer

  2005cited by this paper
• Correlation of Glut-1 glucose transporter expression with [18F]FDG uptake in non-small cell lung cancer

  2000cited by this paper
• Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography.

  2000cited by this paper
• Expression of facilitative glucose transporter isoforms in lung carcinomas: its relation to histologic type, differentiation grade, and tumor stage.

  1998cited by this paper
• Quantitation in Positron Emission Computed Tomography: 1. Effect of Object Size

  1979cited by this paper

• Prediction of programmed death-ligand 1 expression levels in non-small cell lung cancer patients based on 18F-fluorodeoxyglucose PET/computed tomography radiomics features.

  2026cites this paper
• Correlación entre los parámetros metabólicos derivados de la PET/TC con [18F]FDG y la expresión de PD-L1 en pacientes con cáncer de pulmón no microcítico

  2026cites this paper
• Correlation between F-18 FDG PET/CT-derived metabolic parameters and PD-L1 expression in non-small cell lung cancer patients.

  2025cites this paper
• High PD-L1 expression correlates with lymph node metastasis in patients who have undergone radical surgery for primary pulmonary adenocarcinoma

  2025cites this paper
• The predictive value of total body PET/CT in high PD-L1 expression and immunotherapy in advanced non-small cell lung cancer patients

  2025cites this paper
• Head-to-head comparison of peptide-based and nanobody-based radiotracers in detecting PD-L1 expression in non-small cell lung cancer

  2025cites this paper
• Using 18F-FDG PET/CT to predict programmed cell death ligand expression in non-small cell lung cancer via metabolic tumour heterogeneity

  2025influential citation
• Predicting PD-L1 in Lung Adenocarcinoma Using 18F-FDG PET/CT Radiomic Features

  2025cites this paper
• 18F-FDG PET/CT for prediction of PD-L1 expression and tumor mutational burden in non-small cell lung cancer: biomarkers prediction models development and immunotherapy responses verification

  2025cites this paper
• Clinical feasibility study of early 30-minute dynamic FDG-PET scanning protocol for patients with lung lesions

  2024cites this paper
• Critères d’évaluation de la TEP au 18F-FDG au cours de l’immunothérapie

  2024cites this paper
• Outcome prediction based on [18F]FDG PET/CT in patients with pleural mesothelioma treated with ipilimumab and nivolumab +/- UV1 telomerase vaccine

  2024cites this paper
• Texture Features of 18F-Fluorodeoxyglucose Positron Emission Tomography for Predicting Programmed Death-Ligand-1 Levels in Non-Small Cell Lung Cancer

  2024cites this paper
• Predicting programmed death-ligand 1 (PD-L1) expression with fluorine-18 fluorodeoxyglucose ([18F]FDG) positron emission tomography/computed tomography (PET/CT) metabolic parameters in resectable non-small cell lung cancer

  2024cites this paper
• 18F-FDG PET/CT for evaluation of metastases in nonsmall cell lung cancer on the efficacy of immunotherapy

  2023cites this paper
• Opportunities and challenges in combining immunotherapy and radiotherapy in esophageal cancer

  2023cites this paper
• PD-L1 expression correlation with metabolic parameters of 18F-FDG PET/CT in nonsmall cell lung cancer

  2023cites this paper
• Value of 18F-FDG PET/CT Based on PD-L1 to Predict Outcomes of Immunotherapy in NSCLC

  2023cites this paper
• The role of PET molecular imaging in immune checkpoint inhibitor therapy in lung cancer: Precision medicine and visual monitoring.

  2022cites this paper
• Prognostic value of 18F-FDG PET/CT in patients with advanced or metastatic non-small-cell lung cancer treated with immune checkpoint inhibitors: A systematic review and meta-analysis

  2022influential citation
• Research progress on the intrinsic non-immune function of PD-L1 in tumors (Review)

  2022cites this paper
• The predictive value of total-body PET/CT in non-small cell lung cancer for the PD-L1 high expression

  2022cites this paper
• Predictive value of baseline metabolic tumor volume for non-small-cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis

  2022cites this paper
• Monitoring of Current Cancer Therapy by Positron Emission Tomography and Possible Role of Radiomics Assessment

  2022cites this paper
• Prognostic Potential of Metabolic Activity on 18F-FDG Accumulation in Advanced NSCLC Receiving Combining Chemotherapy Plus PD-1 Blockade

  2022cites this paper
• Prospective assessment using 18F-FDG PET/CT as a novel predictor for early response to PD-1 blockade in non-small-cell lung cancer

  2022cites this paper
• Dynamic 18F‐FDG PET/CT can predict the major pathological response to neoadjuvant immunotherapy in non‐small cell lung cancer

  2022cites this paper
• The correlation between PD-L1 expression and metabolic parameters of 18FDG PET/CT and the prognostic value of PD-L1 in non-small cell lung cancer.

  2022cites this paper
• 18F FDG PET/CT and Novel Molecular Imaging for Directing Immunotherapy in Cancer.

  2022cites this paper
• Application of Molecular Imaging in Immune Checkpoints Therapy: From Response Assessment to Prognosis Prediction.

  2022cites this paper
• Prognostic Significance of PD-L1 Expression and Standardized Uptake Values in the Primary Lesions of Stage IV Adenocarcinoma Lung Cancer

  2022cites this paper
• The “digital biopsy” in non-small cell lung cancer (NSCLC): a pilot study to predict the PD-L1 status from radiomics features of [18F]FDG PET/CT

  2022cites this paper
• Visual Assessment of 18F-FDG Uptake on PET to Predict Survival Benefit to PD-1 Blockade in Non–Small Cell Lung Cancer

  2022cites this paper
• Imaging the Rewired Metabolism in Lung Cancer in Relation to Immune Therapy

  2022cites this paper
• Correlation of epidermal growth factor receptor mutation status and PD-L1 expression with [18F]FDG PET using volume-based parameters in non-small cell lung cancer

  2021cites this paper
• Applications of FDG PET in Oncology: Best Clinical Practice

  2021cites this paper
• Immuno-PET imaging of 68Ga-labeled nanobody Nb109 for dynamic monitoring the PD-L1 expression in cancers

  2021cites this paper
• Radiological assessment of response and adverse events associated with novel systemic oncological therapies.

  2021cites this paper
• Value of 18F-FDG-PET to predict PD-L1 expression and outcomes of PD-1 inhibition therapy in human cancers

  2021cites this paper
• Association between 18F-FDG metabolic activity and programmed death ligand-1 (PD-L1) expression using 22C3 immunohistochemistry assays in non-small cell lung cancer (NSCLC) resection specimens.

  2021cites this paper
• The Value of 18F-FDG PET/CT in Predicting the Response to PD-1 Blocking Immunotherapy in Advanced NSCLC Patients with High-Level PD-L1 Expression.

  2021cites this paper
• Impact of Metabolic Activity in Hepatocellular Carcinoma: Association With Immune Status and Vascular Formation

  2021cites this paper
• Response Prediction and Evaluation Using PET in Patients with Solid Tumors Treated with Immunotherapy

  2021cites this paper
• Diagnostic test accuracy of 18F-FDG PET/CT for prediction of programmed death ligand 1 (PD-L1) expression in solid tumours: a meta-analysis.

  2021cites this paper
• Combining PD-L1 Expression and Standardized Uptake Values in FDG-PET/CT Can Predict Prognosis in Patients With Resectable Non–Small-Cell Lung Cancer

  2021cites this paper
• The Combination of Radiotherapy With Immunotherapy and Potential Predictive Biomarkers for Treatment of Non-Small Cell Lung Cancer Patients

  2021cites this paper
• Immune Checkpoint Inhibitors in Advanced NSCLC: [18F]FDG PET/CT as a Troubleshooter in Treatment Response

  2021cites this paper
• Immunotherapy Monitoring with Immune Checkpoint Inhibitors Based on [18F]FDG PET/CT in Metastatic Melanomas and Lung Cancer

  2021cites this paper
• Pseudoprogression in lung cancer patients treated with immunotherapy.

  2021cites this paper
• FDG PET and CT radiomics in diagnosis and prognosis of non-small-cell lung cancer

  2021cites this paper
• Usefulness of [18F]fluorodeoxyglucose PET/CT for evaluating the PD-L1 status in nasopharyngeal carcinoma

  2020cites this paper
• The Role of 18F-FDG-PET as Therapeutic Monitoring in Patients with Lung Cancer

  2020cites this paper
• Response evaluation after immunotherapy in NSCLC

  2020cites this paper
• Evaluation of programmed death 1 (PD-1) and programmed death ligand-1 (PD-L1) as tumor biomarkers an in patients with head and neck squamous cell carcinoma

  2020cites this paper
• KPNB1-mediated nuclear translocation of PD-L1 promotes non-small cell lung cancer cell proliferation via the Gas6/MerTK signaling pathway

  2020cites this paper
• Correlation Between Dual-Time-Point FDG PET and Tumor Microenvironment Immune Types in Non-Small Cell Lung Cancer

  2020cites this paper
• The potential of 18F-FDG PET/CT in predicting PDL1 expression status in pulmonary lesions of untreated stage IIIB-IV non-small-cell lung cancer.

  2020cites this paper
• Assessing Immunotherapy with Functional and Molecular Imaging and Radiomics.

  2020cites this paper
• Predictive value of 18F‐fluorodeoxyglucose positron emission tomography/computed tomography for PD‐L1 expression in non‐small cell lung cancer: A systematic review and meta‐analysis

  2020cites this paper
• Tumor metabolic volume by 18F-FDG-PET as a prognostic predictor of first-line pembrolizumab for NSCLC patients with PD-L1 ≥ 50%

  2020cites this paper
• PD-L1 in Lung Adenocarcinoma: Insights into the Role of 18F-FDG PET/CT

  2020cites this paper
• Relationship between SP142 PD-L1 Expression and 18F-FDG Uptake in Non-Small-Cell Lung Cancer

  2020cites this paper
• Construction of a prognostic model for lung adenocarcinoma based on bioinformatics analysis of metabolic genes

  2020cites this paper
• PD-L1 expression correlation with metabolic parameters of FDG PET/CT and clinicopathological characteristics in non-small cell lung cancer

  2020influential citation
• 18F-FDG PET/CT to predict tumor PD-L1 expression and response to PD-(L)1 blockade in patients with non-small-cell lung cancer

  2020cites this paper
• Potential of FDG-PET as Prognostic Significance after anti-PD-1 Antibody against Patients with Previously Treated Non-Small Cell Lung Cancer

  2020cites this paper
• 18F-FDG maximum standard uptake value predicts PD-L1 expression on tumor cells or tumor-infiltrating immune cells in non-small cell lung cancer

  2020cites this paper
• The importance of FDG-PET/CT parameters for the assessment of the immune status in advanced HNSCC.

  2020cites this paper
• Correlation of PD-L1 expression on tumor cell and tumor infiltrating immune cell with 18F-fluorodeoxyglucose uptake on PET/computed tomography in surgically resected pulmonary adenocarcinoma

  2020cites this paper
• Comprehensive analysis of the association between tumor glycolysis and immune/inflammation function in breast cancer

  2020cites this paper
• The efficiency of 18F-FDG PET-CT for predicting the major pathologic response to the neoadjuvant PD-1 blockade in resectable non-small cell lung cancer

  2020cites this paper
• Tumor immunity is related to 18F‐FDG uptake in thymic epithelial tumor

  2020cites this paper
• Fluorodeoxyglucose uptake is associated with low tumor-infiltrating lymphocyte levels in patients with small cell lung cancer.

  2019cites this paper
• Preliminary data on circulating tumor cells in metastatic NSCLC patients candidate to immunotherapy.

  2019cites this paper
• Relationship Between Tumor Immune Markers and Fluorine-18-α-Methyltyrosine ([18F]FAMT) Uptake in Patients with Lung Cancer

  2019cites this paper
• The prediction of response to immunotherapy in non-small cell lung cancer patients by 18F-FDG PET/CT.

  2019cites this paper
• F-FDG Uptake Is Predictive of Poor Survival After Surgery for Large-CellNeuroendocrine-Carcinomas of The Lung: A Bicentric Analysis

  2019cites this paper
• 18F-FDG uptake in PET/CT is a potential predictive biomarker of response to anti-PD-1 antibody therapy in non-small cell lung cancer

  2019cites this paper
• Noninvasive imaging in cancer immunotherapy: the way to precision medicine.

  2019cites this paper
• Independent expression of circulating and tissue levels of PD-L1: correlation of clusters with tumor metabolism and outcome in patients with non-small cell lung cancer

  2019cites this paper
• F-FDG PET/CT in non-small-cell lung cancer patients: a potential predictive biomarker of response to immunotherapy

  2019cites this paper
• Clinical and Biological Significance of PD-L1 Expression Within the Tumor Microenvironment of Oral Squamous Cell Carcinoma

  2019cites this paper
• Association between peripheral blood markers and immune-related factors on tumor cells in patients with resected primary lung adenocarcinoma

  2019cites this paper
• 18F-FDG PET/CT in non-small-cell lung cancer patients: a potential predictive biomarker of response to immunotherapy.

  2019cites this paper
• Prevalence and prognostic value of PD-L1 expression in molecular subtypes of metastatic large cell neuroendocrine carcinoma (LCNEC).

  2019cites this paper
• Association of preoperative serum CRP with PD-L1 expression in 508 patients with non-small cell lung cancer: A comprehensive analysis of systemic inflammatory markers.

  2018cites this paper
• Standardized Uptake Values Derived from 18F-FDG PET May Predict Lung Cancer Microvessel Density and Expression of KI 67, VEGF, and HIF-1α but Not Expression of Cyclin D1, PCNA, EGFR, PD L1, and p53

  2018cites this paper
• Immunotherapy in non-small-cell lung cancer: potential predictors of response and new strategies to assess activity.

  2018cites this paper
• 18F-FDG PET/CT for response assessment in Hodgkin lymphoma undergoing immunotherapy with checkpoint inhibitors

  2018cites this paper
• 2-Deoxy-2-[fluorine-18] fluoro-d-glucose uptake on positron emission tomography is associated with programmed death ligand-1 expression in patients with pulmonary adenocarcinoma.

  2018cites this paper
• Radiological Features of IDO1+/PDL1+ Lung Adenocarcinoma: A Retrospective Single-institution Study

  2018cites this paper
• PD-L2 Expression as a Potential Predictive Biomarker for the Response to Anti-PD-1 Drugs in Patients with Non-small Cell Lung Cancer

  2018cites this paper
• Radiological Features of Programmed Cell Death-Ligand 2-positive Lung Adenocarcinoma: A Single-institution Retrospective Study

  2018cites this paper
• Imaging of immunotherapy response in non-small cell lung cancer: challenges and perspectives

  2018cites this paper
• FDG PET/CT for assessing tumour response to immunotherapy

  2018cites this paper
• Non-small cell lung carcinoma: understanding cancer microenvironment to drive immunotherapy and patients’ selection

  2018cites this paper
• Is it time to change our vision of tumor metabolism prior to immunotherapy?

  2018cites this paper
• Metabolic characteristics of programmed cell death‐ligand 1‐expressing lung cancer on 18F‐fluorodeoxyglucose positron emission tomography/computed tomography

  2017cites this paper